NFE2L2 and breast adenocarcinoma: It was shown that inhibition of Nrf2 with Nrf2 inhibitor strongly increased the reaction of three cancer cell lines, neuroblastoma, breast adenocarcinoma and non-small cell lung carcinoma to anticancer drugs [24].